NeoAlchemy Clinical: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
NeoAlchemy Clinical
Largest movements
- Current investments +€85,128
new in 2025: €85,128
- Cash +€24,459
up €24,459 (+210%), from €11,675 to €36,134
mainly Net result for the year (+€104,894) and Tax, wage and social debts (+€29,686)
- Receivables within one year -€16,117
down €16,117 (-48.8%), from €32,993 to €16,876
of which Trade receivables: -€15,602
- Profit (loss) carried forward +€67,694
up €67,694 (+11,871%), from €570 to €68,265
- Tax, wage and social debts +€29,686
up €29,686 (+339%), from €8,745 to €38,431
- Trade debts -€1,706
down €1,706 (-78.6%), from €2,172 to €465
- Gross operating margin +€117,458
up €117,458 (+587%), from €20,010 to €137,468
- Taxes +€26,133
up €26,133 (+616%), from €4,245 to €30,378
- Financial charges +€1,997
up €1,997 (+1,380%), from €145 to €2,141
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €45,547 | €140,213 | +€94,666 | +208% |
| Current assets | 29/58 | €45,547 | €140,213 | +€94,666 | +208% |
| Amounts receivable within one year | 40/41 | €32,993 | €16,876 | -€16,117 | -48.8% |
| Trade receivables | 40 | €30,728 | €15,126 | -€15,602 | -50.8% |
| Other amounts receivable | 41 | €2,265 | €1,750 | -€515 | -22.7% |
| Current investments | 50/53 | - | €85,128 | +€85,128 | |
| Cash at bank and in hand | 54/58 | €11,675 | €36,134 | +€24,459 | +210% |
| Deferred charges and accrued income | 490/1 | €879 | €2,075 | +€1,196 | +136% |
| Total equity and liabilities | 10/49 | €45,547 | €140,213 | +€94,666 | +208% |
| Equity | 10/15 | €3,570 | €71,265 | +€67,694 | +1,896% |
| Contributions | 10/11 | €3,000 | €3,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €570 | €68,265 | +€67,694 | +11,871% |
| Amounts payable | 17/49 | €41,977 | €68,948 | +€26,972 | +64.3% |
| Amounts payable within one year | 42/48 | €41,977 | €68,948 | +€26,972 | +64.3% |
| Trade debts | 44 | €2,172 | €465 | -€1,706 | -78.6% |
| Suppliers | 440/4 | €2,172 | €465 | -€1,706 | -78.6% |
| Taxes, remuneration and social security | 45 | €8,745 | €38,431 | +€29,686 | +339% |
| Taxes | 450/3 | €8,745 | €38,431 | +€29,686 | +339% |
| Other amounts payable | 47/48 | €31,060 | €30,052 | -€1,008 | -3.2% |
| Other operating charges | 640/8 | €50 | €63 | +€13 | +25.2% |
| Gross operating margin | 9900 | €20,010 | €137,468 | +€117,458 | +587% |
| Operating profit (loss) | 9901 | €19,960 | €137,405 | +€117,445 | +588% |
| Financial income | 75/76B | €0 | €8 | +€8 | +81,800% |
| Recurring financial income | 75 | €0 | €8 | +€8 | +81,800% |
| Financial charges | 65/66B | €145 | €2,141 | +€1,997 | +1,380% |
| Recurring financial charges | 65 | €145 | €2,141 | +€1,997 | +1,380% |
| Profit (loss) for the period before taxes | 9903 | €19,815 | €135,272 | +€115,457 | +583% |
| Income taxes | 67/77 | €4,245 | €30,378 | +€26,133 | +616% |
| Profit (loss) for the period | 9904 | €15,570 | €104,894 | +€89,324 | +574% |
| Profit (loss) for the period to be appropriated | 9905 | €15,570 | €104,894 | +€89,324 | +574% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 1 November 2026 via checked.be.